Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
425 - Onconetix, Inc. (0001782107) (Subject)
425 - Onconetix, Inc. (0001782107) (Subject)
DEF 14A - Onconetix, Inc. (0001782107) (Filer)
Realbotix Announces Expected Delivery of 19 Robots in March, April, and May 2026 as it Scales Production Capacity; Onconetix recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a subsidiary of Realbotix Corp. CINCINNATI, Ohio, April 02, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC ("Realbotix"), the target of Onconetix's previously announced pending acquisition. On April 1, 2026, Realbotix announced that it expects to deliver 19 previously ordered robots and corresponding AI implementations for months of March, April, and
Experienced Leadership Team Positioned to Execute Pending Transformative Acquisition of Realbotix LLC and Drive Long-Term Shareholder Value CINCINNATI, Ohio, March 31, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company") today announced the appointment of David White as Chief Executive Officer, effective March 18, 2026, and the appointment of Sammy Dorf as a member of the Company's Board of Directors and the Audit Committee, effective March 19, 2026. Karina Fedasz, the Company's outgoing Interim Chief Executive Officer, will continue to serve as its Interim Chief Financial Officer. These appointments reflect the Company's commitment to assembling experien
CINCINNATI, Ohio, March 23, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ:ONCO) ("Onconetix" or the "Company"), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today announced that its Board of Directors (the "Board of Directors" or "Board") has approved a 1-for-5 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. Eastern Time on March 25, 2026. On February 3, 2026, Onconetix held a special meeting of stockholders (the "Special Meeting"), at which the Company's stockholders approved a proposal to effect a reverse split, at a ratio in
3 - Onconetix, Inc. (0001782107) (Issuer)
3 - Onconetix, Inc. (0001782107) (Issuer)
3 - Onconetix, Inc. (0001782107) (Issuer)
Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising
SC 13G - Onconetix, Inc. (0001782107) (Subject)
SC 13D - Onconetix, Inc. (0001782107) (Subject)
SC 13D - Onconetix, Inc. (0001782107) (Subject)